AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Emeryville ca 4d molecular therapeutics9/16/2023 This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied. 4DMT is a leader in next-generation AAV gene therapy discovery through its. This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Emeryville, CA, USA San Francisco, CA, USA. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. We anticipate that subsequent events and developments will cause our views to change. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, and objectives of management, are forward looking statements. This Presentation contains forward looking statements that involve substantial risks and uncertainties. Inventor on patents and pending patent applications related to AAV capsid variants and AAV gene delivery. It is expected to price during the week of December 7, 2020.4D Molecular Therapeutics : 710 AEROW Phase 1/2 Interim Clinical Data Presentation – June 2023 Chief Scientific Officer & a full-time employee at 4D Molecular Therapeutics, Inc. Goldman Sachs, BofA Securities and Evercore ISI are the joint bookrunners on the deal. It plans to list on the Nasdaq under the symbol FDMT. It has two additional candidates that it expects to file INDs for in the 2H21.ĤD Molecular Therapeutics was founded in 2013 and booked $17 million in collaboration and license revenue for the 12 months ended September 30, 2020. 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease. Its lead candidates include 4D-125, which is currently in a Phase 1/2 trial for X-linked retinitis pigmentosa with initial data expected in 2021 4D-110, which is currently in a Phase 1 trial for choroideremia with initial data expected in 2022 and 4D-310, which is currently in a Phase 1/2 trial for Fabry disease with initial data expected in 2021. Alumni, Venture-Backed 4D Molecular Therapeutcs. At the midpoint of the proposed range, 4D Molecular Therapeutics would command a fully diluted market value of $491 million.ĤD is developing product candidates using its targeted and evolved AAV vectors, initially focusing on ophthalmology, cardiology, and pulmonology. The Emeryville, CA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. 4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, announced terms for its IPO on Monday.
0 Comments
Read More
Leave a Reply. |